Diagnostic kit for real-time monitoring resistance in targeted cancer therapy
Targeted drug is common in cancer therapy. Immuno-oncology drugs only effect in 10-25％ cancers. CAR-T tumor immunotherapies only treat small number leukemias. Drug resistances may occur post-therapy: Some patients innately don't respond to a targeted drug in initial treatment; Tumor may develop resistance against an initial effective drug post-0.6-2 years. Drug resistances are often detected too late and cause mortality with CT scan 3 months post-therapy. About 60% drug resistances are not relative to current known oncogene, undetectable by liquid biopsy (ctDNA, CTC, exosome gene assay); their results often false-negative. Current liquid biopsy delay disease treatments, since presence of CTC or ctDNA indicate resistant tumors had metastasized earlier. By directly assaying serum biomarker downstream of oncoproteins that targeted drugs are acting, clinical trials showed our liquid biopsy IVD kit early (2-weeks post-therapy) and “truly” real-time monitor therapy resistance of most drugs and most cancer types, solve problems of CT, liquid biopsy in detecting resistance, help patients get correct drug in time. Our product can facilitate precision medicine; help CT and liquid biopsy get real-time monitoring resistance ability, save cancer treatment expenses.